Karlo Gjuras has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Stress before the event, care after: Psychosocial stressors, psychiatric care, and cardiac rehabilitation after early-onset myocardial infarction

    by Hrvoje Jurin, Ivana Jurin, Matias Trbušić, Tomislava Bodrožić Džakić Poljak, Karlo Gjuras, Ivan Skorić, Irzal Hadžibegović, Ivan Zeljković, Sara Milić, Fran Rode, et al.

  • Open Access

    Documented Rheumatic Disease and Post-Discharge Mortality After Acute Coronary Syndrome: A Two-Center Registry Study

    by Ivana Jurin, Stela Hrkač, Goran Šukara, Irzal Hadžibegović, Karlo Gjuras, Andrija Matijević, Diana Rudan, Šime Manola, Denis Došen, Kristina Marić Bešić, et al.

    Background and Objectives: Rheumatic diseases confer excess cardiovascular risk, yet prognosis after acute coronary syndrome (ACS) in contemporary angiography-treated care remains incompletely characterized, particularly when psychiatric multimorbidity is considered. We evaluated whether documented rheumatic disease was associated with psychiatric comorbidity and post-discharge mortality after ACS. Materials and Methods: We retrospectively analyzed a predefined two-center registry extract of 2950 consecutive patients who underwent coronary angiography for ACS. Documented rheumatic disease was identified from diagnoses recorded in admission history, prior medical records, or discharge documentation and was not re-adjudicated. The primary outcome was post-discharge all-cause mortality. Results: Documented rheumatic disease was present in 106 patients (3.6%). Compared with patients without documented rheumatic disease, exposed patients were older, more often women, more often hypertensive, and more likely to have a documented psychiatric disorder (25.5% vs. 14.1%). Short-term mortality was similar, whereas crude overall long-term mortality was higher (27.4% vs. 19.3%). Among hospital survivors with usable follow-up, post-discharge survival was worse (log-rank p = 0.013). Documented rheumatic disease was associated with higher post-discharge mortality in unadjusted analysis (hazard ratio 1.66, 95% confidence interval 1.11–2.48) and in a prespecified parsimonious model (adjusted hazard ratio 1.56, 95% confidence interval 1.04–2.34); the association attenuated and was no longer statistically significant in a broader exploratory model (adjusted hazard ratio 1.35, 95% confidence interval 0.87–2.07). Documented psychiatric disorder independently predicted mortality. Conclusions: In angiography-treated ACS, documented rheumatic disease was associated with greater psychiatric comorbidity and worse post-discharge survival in a small, documentation-defined, heterogeneous subgroup. Because the signal attenuated in broader exploratory adjustment and exposure ascertainment was documentation-based, the findings should be regarded as hypothesis-generating rather than disease-specific or causal.

  • GLP-1 Receptor Agonist Semaglutide and SGLT2 Inhibitors after Acute Coronary Syndrome in Patients with Diabetes: Real-World Comparative Outcomes from an Observational Registry

    by Ivana Jurin, Karlo Gjuras, Dijana Bešić, Hrvoje Jurin, Jelena Kursar, Tea-Terezija Cvetko, Fran Rode, Tomislav Šipić, Petar Lišnjić, Šime Manola, et al.

    Introduction: Patients with type 2 diabetes (T2D) remain at high cardiovascular risk after acute coronary syndrome (ACS), particularly after myocardial infarction (MI). Evidence on the early post-ACS use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly semaglutide, and sodium-glucose cotransporter-2 inhibitors (SGLT2i) is limited. Methods: We analyzed 870 patients in the registry-based T2D cohort discharged after ACS from the single-center Cardiology Research Dubrava (CaRD) registry (2017–2025). Patients were grouped according to discharge therapy: no GLP-1RA/SGLT2i, GLP-1RA only (semaglutide), SGLT2i only, or combined therapy. Descriptive outcomes included all-cause mortality and a broad registry composite of clinical events. To better address baseline imbalances and unequal group sizes, adjusted Cox models focused on conventional 3-point major adverse cardiovascular events (3P-MACEs: cardiovascular death, nonfatal MI, or nonfatal stroke) and included age, sex, ACS type, estimated glomerular filtration rate, body mass index (BMI), left ventricular ejection fraction (LVEF), hemoglobin A1c (HbA1c), and low-density lipoprotein cholesterol. Results: The median age was 68 years, and 67.5% of participants were male. Discharge therapy included no GLP-1RA/SGLT2i (n = 484), GLP-1RA (n = 35), SGLT2i (n = 277), and combined GLP-1RA+SGLT2i (n = 74), indicating substantial imbalance in subgroup size. During a median follow-up of 37 months, all-cause mortality was highest in the control group (30.2%) and lowest with combined therapy (2.7%), in which no cardiovascular deaths were recorded. However, important baseline differences in BMI, HbA1c, LVEF, age, and socioeconomic characteristics were present across groups. In adjusted 3P-MACE models, adherence to GLP-1RA and/or SGLT2i was associated with lower risk (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.37–0.82, p = 0.003). When entered separately, SGLT2i remained significant (HR 0.66, 95% CI 0.44–0.99, p = 0.042), whereas GLP-1RA showed a similar direction of association but did not retain statistical significance (HR 0.60, 95% CI 0.28–1.28, p = 0.189). Conclusion: In this single-center observational ACS registry, semaglutide and SGLT2i use were associated with more favorable cardiometabolic profiles and lower event rates after discharge. The apparent benefit of combined therapy should be interpreted cautiously because of small subgroup sizes. These results are hypothesis-generating and support further prospective evaluation of combined cardiometabolic therapy after ACS.

  • Thyroid function, coronary complexity, and socio-demographic determinants of outcomes after acute coronary syndrome: sex-specific analysis from the CaRD registry

    by Ivana Jurin, Karlo Gjuras, Maja Banović, Tea-Terezija Cvetko, Ana Matijaca, Irzal Hadžibegović, Kristina Marić Bešić, Šime Manola, Hrvoje Jurin, Diana Rudan, et al.


  • Open Access

    Prognostic Impact of Frailty in Transcatheter Aortic Valve Implantation

    by Ivana Jurin, Daniel Unić, Nikola Pavlović, Marin Pavlov, Savica Gjorgjievska, Tomislav Šipić, Šime Manola, Igor Rudež, Ana Šerman, Antonio Bulum, et al.

    Background: Frailty strongly influences outcomes after transcatheter aortic valve implantation (TAVI), but conventional risk models insufficiently capture functional and cognitive vulnerability. We compared conventional surgical risk scores with multidimensional frailty assessment and a biological score. Methods: This observational registry included 528 consecutive patients with severe symptomatic aortic stenosis undergoing TAVI between January 2019 and November 2024. Frailty was assessed using the Essential Frailty Toolset (EFT), Katz Index, and cognitive screening, alongside French Aortic National CoreValve and Edwards 2 (FRANCE-2) and Age, Creatinine, and Ejection Fraction (ACEF) scores. HALP was calculated as (haemoglobin × albumin × lymphocytes) ÷ platelets. Primary endpoints were 30-day, 6-month, and 1-year all-cause mortality. Secondary outcomes included non-fatal major adverse cardiovascular events (MACE), complications, and quality-of-life improvement. Results: One-year mortality was 12.7%. EFT and Katz Index showed the strongest discrimination for 1-year mortality (AUC 0.72 and 0.75), outperforming EuroSCORE II and STS-PROM (AUC 0.66 and 0.68). After adjustment, EFT (HR 1.91, 95% CI 1.47–2.48), Katz Index (HR 0.57, 95% CI 0.47–0.70, and cognitive impairment (HR 2.24, 95% CI 1.34–3.75) independently predicted 1-year mortality. HALP was not associated with outcomes. FRANCE-2 independently predicted 1-year MACE (HR 1.24, p = 0.019). Conclusions: Functional frailty and cognitive impairment add prognostic value beyond conventional comparator models, whereas HALP does not. Brief functional and cognitive screening may help Heart Teams identify patients who need closer peri-procedural optimisation, rehabilitation planning, and discharge support rather than relying on surgical risk scores alone.


  • Open Access

    Two-Year Implementation, Adherence, and Outcomes of Quadruple Guideline-Directed Medical Therapy in Newly Diagnosed HFrEF: Insights from the Prospective CaRD Registry

    by Ivana Jurin, Daniel Lovrić, Karlo Gjuras, Šime Manola, Irzal Hadžibegović, Mario Udovičić, Diana Rudan, Anica Milinković, Jasmina Ćatić, Marija Križanović, et al.

    Background: Contemporary guidelines recommend rapid initiation of four classes of guideline-directed medical therapy (GDMT) for heart failure (HF) with reduced ejection fraction (HFrEF); however, real-world persistence, adherence, and dose optimization remain suboptimal. Methods: We analysed a predefined subregistry within the prospective Cardiology Research Dubrava (CaRD) registry, a real-world HF registry at a tertiary centre that includes patients across the ejection-fraction spectrum in whom contemporary HF therapy, including sodium-glucose cotransporter 2 inhibitors (SGLT2i), is introduced or optimised in routine practice. For this analysis, we included patients with newly diagnosed HFrEF (left ventricular ejection fraction (LVEF) ≤ 40%) who were discharged on all four GDMT classes; 167 of 179 patients with newly diagnosed HFrEF during the study period had an available 6-month medication assessment and comprised the final analytic cohort. The four GDMT pillars (beta-blocker; angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), or angiotensin receptor-neprilysin inhibitor (ARNI); mineralocorticoid receptor antagonist (MRA); and SGLT2i) were initiated within 4 days when clinically feasible. Medication adherence and target-dose attainment were assessed at 6, 12, and 24 months using a structured self-report questionnaire. Major adverse events (MAE) and all-cause mortality were recorded over 24 months. Patients were classified as adherent if they reported regular intake (≥80% of prescribed doses) of all four drug classes at 6 months; otherwise, they were classified as nonadherent. Results: Among the 167 analysed patients (median age 64 years, 74% men, median LVEF 30%), regular adherence at 6, 12, and 24 months was 65%, 55%, and 59% for beta-blockers; 66%, 50%, and 49% for ACEi/ARB/ARNI; 62%, 52%, and 49% for MRAs; and 84%, 57%, and 68% for SGLT2i. Target doses were achieved in 25–33% for beta-blockers, 42–50% for ACEi/ARB/ARNI, and 73–78% for MRAs. At 24 months, 56 survivors (37%) were adherent to all four drug classes. Over 24 months, all-cause mortality was 9.0% and MAE 18.6%, occurring less frequently in adherent vs. nonadherent patients (mortality 0% vs. 13.5%; MAE 8.9% vs. 23.4%). Conclusions: In this real-world, non-randomized HFrEF subregistry, in-hospital initiation of quadruple GDMT was feasible, yet maintaining long-term adherence and achieving target doses remained challenging. These data underscore the gap between guideline recommendations and routine practice and support structured follow-up and protocol-driven titration to optimize implementation.


  • Open Access

    Real-World Patterns and Outcomes of Anticoagulation Therapy in Pulmonary Embolism: An Observational Dual-Centre Registry Analysis

    by Ivana Jurin, Josip Pejić, Karlo Gjuras, Fran Šaler, Tea-Terezija Cvetko, Nevenka Piskač Živković, Zdravko Mitrović, Šime Manola, Marin Pavlov, Aleksandar Blivajs, et al.

    Background: Pulmonary embolism (PE) is a major cause of cardiovascular morbidity and mortality. Guidelines favor direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs), but real-world Croatian data are scarce. Methods: A prospective dual-center registry included 773 patients discharged with acute PE between 2013 and 2024. Clinical, laboratory, and socioeconomic data were collected. The primary outcome was all-cause mortality; secondary outcomes were recurrent venous thromboembolism (VTE) and major bleeding. Results: DOAC users were younger, with higher education and income, than VKA or heparin patients. Median follow-up was 1106 days. Mortality reached 60.3% with VKA, 26.0% with DOAC, and 84.1% with heparin (p < 0.001). VTE recurrence did not differ significantly. Major bleeding occurred in 9.3% of VKA versus 2.9% of DOAC patients (p = 0.003). Adjusted analysis showed a lower mortality risk with DOAC versus VKA (HR 0.62, 95% CI 0.48–0.80, p < 0.001), while heparin predicted higher mortality (HR 3.63, 95% CI 2.54–5.21, p < 0.001). Higher PESI class independently increased mortality and recurrence. Conclusion: In the first Croatian PE cohort, DOACs were linked to reduced mortality and bleeding risk compared with VKAs, with similar recurrence. Clinical, socioeconomic, and policy factors strongly influenced prescribing patterns and outcomes.


  • Is unprovoked pulmonary embolism a red flag for occult malignancy?

    by Karlo Gjuras, Dijana Bešić, Iva Saraja, Marija Križanović, Kristina Marić Bešić, Ivana Jurin

  • Open Access

    Acute Coronary Syndrome Management in Older Patients: A Dual-Center Retrospective Cohort Study

    by Karlo Gjuras, Ivana Jurin, Hrvoje Jurin, Eduard Margetić, Boško Skorić, Joško Bulum, Irzal Hadžibegović, Ivan Zeljković, Marin Pavlov, Šime Manola, et al.

    Background and Objectives: Older patients with ACS are less frequently treated with an invasive strategy, which may negatively impact their survival. This study aimed to investigate treatment approaches in elderly ACS patients and compare outcomes between invasively and conservatively treated groups. Materials and Methods: This retrospective study included consecutive patients aged 80 or older who presented with ACS at two tertiary institutions from November 2018 to October 2023. The invasive group consisted of patients who underwent percutaneous or surgical revascularization. The conservative strategy was defined as guideline-directed medical therapy only. The primary outcome was all-cause mortality during the six-month follow-up. Secondary outcomes were recurrent MI and CVI. Results: Among 670 ACS patients with a median age of 83 years (81–86) and 50.6% women, 429 (64%) were treated with an invasive strategy, and 241 (36%) were treated with a conservative strategy. A total of 176 (26%) patients died during the six-month follow-up period, with significantly higher mortality observed in the conservatively treated group compared to the invasively treated group (ACS: 37.8% vs. 19.3%, p < 0.001; STEMI: 49.4% vs. 26.8%, p < 0.001; NSTE-ACS: 32.1% vs. 10.9%, p < 0.001). Recurrent MI was documented in 2.5% of patients, while CVI occurred in 1.2%, with no difference between the treatment groups. Multivariable regression analysis identified invasive strategy (HR = 0.48; 95% CI: 0.33–0.71; p < 0.001) as a positive predictor of six-month survival in ACS patients. Conclusions: The invasive treatment strategy was associated with lower mortality in older ACS patients, regardless of the type of ACS. The incidence of recurrent MI and CVI did not differ between groups treated with different therapeutic approaches.

  • Open Access

    Tularemija – vrlo rijedak uzrok limfadenopatije u djece

    by Karlo Gjuras, Ivna Tomaš, Lorna Stemberger Marić

    Cilj: Cilj rada je prikazati diferencijalno-dijagnostički izazov u evalvaciji limfadenopatije u pedijatrijskoj populaciji i promišljanje o rijetkim uzrocima kao što je Francisella tularensis. Prikaz slučaja: Osmogodišnji dječak prezentirao se krajem rujna šestodnevnim febrilitetom. Živi u Maloj Mlaci i ima mačku. Negirao je kontakt sa zečevima i ugriz krpelja. Petog dana bolesti na stražnjoj strani desnoga bedra pojavila se papula. Rastom papule nastalo je centralno udubljenje i na kraju je zaostao plitki ulkus. Dva tjedna nakon febriliteta utvrđena je desna ingvinalna limfadenopatija te je zbog sumnje na bolest mačjeg ogreba provedena petodnevna terapija azitromicinom. Zbog perzistencije limfadenopatije i pojave limfadenitisa učinjena je serologija kojom je isključena bartoneloza. Ultrazvučno je u proksimalnom dijelu desne natkoljenice verificiran apsces u supkutanom tkivu. Punkcijom apscesa dobiven je gnojan sadržaj u kojemu je lančanom reakcijom polimeraze dokazan genom F. tularensis. Postavljena je dijagnoza ulceroglandularnog oblika tularemije te je započeta parenteralna terapija gentamicinom tijekom deset dana, a nakon otpusta i peroralna terapija ciprofloksacinom tijekom četiri dana. Zaključak: Tularemija je rijetka bolest, o čemu svjedoči i podatak da su od 2018. do 2022. godine u Hrvatskoj zabilježena samo dva slučaja. Limfadenopatija uzrokovana tularemijom u pedijatrijskoj populaciji predstavlja dijagnostički izazov zbog niske incidencije, pri čemu pozitivna epidemiološka anamneza i postojanje primarnog afekta može pomoći u postavljanju dijagnoze.